I have seen others mention that Intel has the "money and resources" (we can include IBM too for that matter) to throw at their neuromorphic processors. As an engineer, throwing more money or people into a solution isn't always fruitful. I've rephrased a common saying for neutrality, "a human fetus can gestate in approximately nine months, but nine human fetuses cannot gestate in one month".
Depending on the scale of the problem, it might be able to be broken down into smaller pieces that can be worked on in parallel. Additionally, a competitor may spend a lot of money buying time to work around patents researching different approaches. Having more people brainstorm certainly increases the chances of coming up with ideas faster.
I do not believe that the individual components of Brainchip's neuromorphic processor compose a large enough design to continuously scale by adding more people. The competition will have to focus on achieving the same features of Akida using a technical approach that does not infringe upon Brainchip's patents.
At a time when it was unsure as to whether or not neuromorphic processors would be a viable solution, Brainchip found one. They are the first to the commercial market and while they are competitive with their current features set, they are also working on their second and third generation of neuromorphic processors adding even more enhanced functionality.
As long as they don't become complacent due to their current successes, they can continue to profit and acquire the resources to keep innovating their product line. At this point, it is a race to saturate the market with their brand name while continuing to innovate and stay a step ahead of their competitors.
- Forums
- ASX - By Stock
- BRN
- 2022 BRN Discussion
BRN
brainchip holdings ltd
Add to My Watchlist
1.25%
!
20.3¢

2022 BRN Discussion, page-1347
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
20.3¢ |
Change
0.003(1.25%) |
Mkt cap ! $405.0M |
Open | High | Low | Value | Volume |
19.5¢ | 20.5¢ | 19.5¢ | $599.5K | 3.001M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
46 | 480185 | 20.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
20.5¢ | 2883770 | 73 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
44 | 462505 | 0.200 |
75 | 3129600 | 0.195 |
85 | 2307451 | 0.190 |
63 | 2314687 | 0.185 |
81 | 1959232 | 0.180 |
Price($) | Vol. | No. |
---|---|---|
0.205 | 2881884 | 67 |
0.210 | 1483379 | 40 |
0.215 | 990272 | 30 |
0.220 | 1918304 | 45 |
0.225 | 466418 | 9 |
Last trade - 15.25pm 15/07/2025 (20 minute delay) ? |
Featured News
BRN (ASX) Chart |
The Watchlist
CC9
CHARIOT CORPORATION LTD
Shanthar Pathmanathan, MD
Shanthar Pathmanathan
MD
Previous Video
Next Video
SPONSORED BY The Market Online